PMN vs PRFX

ProMIS Neurosciences Inc. vs PRF Technologies Ltd. — Valuation Comparison 2026

PMN

Pharmaceutical Preparations
ProMIS Neurosciences Inc.
Quality
4.2
out of 10
Value Trap
30
LOW
Price
$10.81
Last close
Models
6/13
Active
VS

PRFX

Pharmaceutical Preparations
PRF Technologies Ltd.
Quality
4.4
out of 10
Value Trap
39
LOW
Price
$3.00
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType PMN Fair ValuePMN Upside PRFX Fair ValuePRFX Upside
Bayesian DCF Intrinsic $6.72 -37.9% $2.06 -31.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $10.85 +0.4% $10.26 +242.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PMN vs PRFX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PMN vs PRFX — Which Stock Is More Undervalued?

PRFX scores higher with a 4.4/10 quality rating vs PMN's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ProMIS Neurosciences Inc. (PMN) and PRF Technologies Ltd. (PRFX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PMN currently trades at $10.81 with a QOC of 4.2/10, while PRFX trades at $3.00 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).